418 related articles for article (PubMed ID: 34876702)
1. SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact.
Lipsitch M; Krammer F; Regev-Yochay G; Lustig Y; Balicer RD
Nat Rev Immunol; 2022 Jan; 22(1):57-65. PubMed ID: 34876702
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 vaccine breakthrough infections.
Gupta RK; Topol EJ
Science; 2021 Dec; 374(6575):1561-1562. PubMed ID: 34941414
[TBL] [Abstract][Full Text] [Related]
3. Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine.
Duarte LF; Gálvez NMS; Iturriaga C; Melo-González F; Soto JA; Schultz BM; Urzúa M; González LA; Vázquez Y; Ríos M; Berríos-Rojas RV; Rivera-Pérez D; Moreno-Tapia D; Pacheco GA; Vallejos OP; Hoppe-Elsholz G; Navarrete MS; Rojas Á; Fasce RA; Fernández J; Mora J; Ramírez E; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Bueno SM; Kalergis AM
Front Immunol; 2021; 12():742914. PubMed ID: 34659237
[TBL] [Abstract][Full Text] [Related]
4. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
[TBL] [Abstract][Full Text] [Related]
5. Editorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19.
Parums DV
Med Sci Monit; 2021 Dec; 27():e935624. PubMed ID: 34848673
[TBL] [Abstract][Full Text] [Related]
6. Are COVID-19 Vaccine Boosters Needed? The Science behind Boosters.
Burckhardt RM; Dennehy JJ; Poon LLM; Saif LJ; Enquist LW
J Virol; 2022 Feb; 96(3):e0197321. PubMed ID: 34817198
[TBL] [Abstract][Full Text] [Related]
7. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.
Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR
Elife; 2021 Oct; 10():. PubMed ID: 34636722
[TBL] [Abstract][Full Text] [Related]
8. Modeling the Transmission of the SARS-CoV-2 Delta Variant in a Partially Vaccinated Population.
Avila-Ponce de León U; Avila-Vales E; Huang K
Viruses; 2022 Jan; 14(1):. PubMed ID: 35062363
[TBL] [Abstract][Full Text] [Related]
9. Metabolic disorders, COVID-19 and vaccine-breakthrough infections.
Stefan N
Nat Rev Endocrinol; 2022 Feb; 18(2):75-76. PubMed ID: 34873287
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 vaccinations: The unknowns, challenges, and hopes.
Mohamed K; Rzymski P; Islam MS; Makuku R; Mushtaq A; Khan A; Ivanovska M; Makka SA; Hashem F; Marquez L; Cseprekal O; Filgueiras IS; Fonseca DLM; Mickael E; Ling I; Arero AG; Cuschieri S; Minakova K; Rodríguez-Román E; Abarikwu SO; Faten AB; Grancini G; Cabral-Marques O; Rezaei N
J Med Virol; 2022 Apr; 94(4):1336-1349. PubMed ID: 34845731
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
12. Estimating the number of symptomatic SARS-CoV-2 infections among vaccinated individuals in the United States-January-July, 2021.
Kugeler KJ; Williamson J; Curns AT; Healy JM; Nolen LD; Clark TA; Martin SW; Fischer M
PLoS One; 2022; 17(3):e0264179. PubMed ID: 35263352
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 Vaccine Effectiveness and Breakthrough Infections Among Patients Receiving Maintenance Dialysis.
Manley HJ; Li NC; Aweh GN; Hsu CM; Weiner DE; Miskulin D; Harford AM; Johnson D; Lacson E
Am J Kidney Dis; 2023 Apr; 81(4):406-415. PubMed ID: 36462570
[TBL] [Abstract][Full Text] [Related]
14. Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California.
Servellita V; Morris MK; Sotomayor-Gonzalez A; Gliwa AS; Torres E; Brazer N; Zhou A; Hernandez KT; Sankaran M; Wang B; Wong D; Wang C; Zhang Y; Reyes KR; Glasner D; Deng X; Streithorst J; Miller S; Frias E; Rodgers M; Cloherty G; Hackett J; Hanson C; Wadford D; Philip S; Topper S; Sachdev D; Chiu CY
Nat Microbiol; 2022 Feb; 7(2):277-288. PubMed ID: 35013591
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
Thompson MG; Natarajan K; Irving SA; Rowley EA; Griggs EP; Gaglani M; Klein NP; Grannis SJ; DeSilva MB; Stenehjem E; Reese SE; Dickerson M; Naleway AL; Han J; Konatham D; McEvoy C; Rao S; Dixon BE; Dascomb K; Lewis N; Levy ME; Patel P; Liao IC; Kharbanda AB; Barron MA; Fadel WF; Grisel N; Goddard K; Yang DH; Wondimu MH; Murthy K; Valvi NR; Arndorfer J; Fireman B; Dunne MM; Embi P; Azziz-Baumgartner E; Zerbo O; Bozio CH; Reynolds S; Ferdinands J; Williams J; Link-Gelles R; Schrag SJ; Verani JR; Ball S; Ong TC
MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):139-145. PubMed ID: 35085224
[TBL] [Abstract][Full Text] [Related]
16. Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil.
Estofolete CF; Banho CA; Campos GRF; Marques BC; Sacchetto L; Ullmann LS; Possebon FS; Machado LF; Syrio JD; Araújo Junior JP; Bittar C; Rahal P; Lobo SMA; Ferreira HL; Vasilakis N; Nogueira ML
Viruses; 2021 Jun; 13(7):. PubMed ID: 34206727
[TBL] [Abstract][Full Text] [Related]
17. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK.
Pouwels KB; Pritchard E; Matthews PC; Stoesser N; Eyre DW; Vihta KD; House T; Hay J; Bell JI; Newton JN; Farrar J; Crook D; Cook D; Rourke E; Studley R; Peto TEA; Diamond I; Walker AS
Nat Med; 2021 Dec; 27(12):2127-2135. PubMed ID: 34650248
[TBL] [Abstract][Full Text] [Related]
18. Vaccine nationalism and the dynamics and control of SARS-CoV-2.
Wagner CE; Saad-Roy CM; Morris SE; Baker RE; Mina MJ; Farrar J; Holmes EC; Pybus OG; Graham AL; Emanuel EJ; Levin SA; Metcalf CJE; Grenfell BT
Science; 2021 Sep; 373(6562):eabj7364. PubMed ID: 34404735
[TBL] [Abstract][Full Text] [Related]
19. Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.
Diem G; Jäger M; Dichtl S; Bauer A; Lass-Flörl C; Reindl M; Wilflingseder D; Posch W
Microbiol Spectr; 2023 Jun; 11(3):e0516322. PubMed ID: 37098903
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
Elife; 2022 Jan; 11():. PubMed ID: 35072628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
